AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger

Tie-up would be one of the biggest-ever pharmaceutical deals and create the world’s fourth-largest drugmaker Business live – latest updates Britain’s biggest drugmaker, AstraZeneca, is understood to be in discussions to take over its US rival Bristol Myers Squibb in a deal that would create a near-$400bn (£300bn) pharmaceutical group. AstraZeneca, run by Pascal Soriot, its longtime chief executive, is the second-biggest listed company in the UK, with a market value of nearly £196bn before the news broke. BMS, headquartered in Princeton and known for its cancer treatments, is worth $133bn. Continue reading...

Julia Kollewe · Mon, Aug 3, 2026, 12:58 AM
US news | The Guardian

AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger

Tie-up would be one of the biggest-ever pharmaceutical deals and create the world’s fourth-largest drugmaker

Business live – latest updates

Britain’s biggest drugmaker, AstraZeneca, is understood to be in discussions to take over its US rival Bristol Myers Squibb in a deal that would create a near-$400bn (£300bn) pharmaceutical group.

AstraZeneca, run by Pascal Soriot, its longtime chief executive, is the second-biggest listed company in the UK, with a market value of nearly £196bn before the news broke. BMS, headquartered in Princeton and known for its cancer treatments, is worth $133bn.

This page shows an excerpt; reporting belongs to the original publisher. Some images or embeds may be omitted compared with the live article.